Heron Therapeutics financials
$0.3060+4.87%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $37.7M | $34.7M | $40.6M | $38.2M | $37.2M | $38.9M | $40.8M | $32.8M | $36.0M | $34.7M | $34.2M | $31.4M |
| Gross profit | $26.1M | $24.1M | $29.5M | $26.3M | $27.3M | $30.4M | $30.6M | $23.4M | $25.5M | $26.2M | $24.3M | $13.2M |
| Gross margin | 69.3% | 69.4% | 72.6% | 68.8% | 73.5% | 78.3% | 74.9% | 71.2% | 70.8% | 75.6% | 71.1% | 42.1% |
| Operating income | -$2.0M | -$4.8M | $38.0K | -$4.1M | -$1.6M | $3.2M | $4.2M | -$4.5M | -$6.4M | -$4.8M | -$10.2M | -$24.9M |
| Net income | -$5.5M | -$8.1M | -$3.0M | -$17.5M | -$2.4M | $2.6M | $3.7M | -$4.8M | -$9.2M | -$3.2M | -$10.7M | -$25.0M |
| Net margin | −14.6% | −23.4% | −7.3% | −45.8% | −6.4% | 6.8% | 9.0% | −14.8% | −25.6% | −9.1% | −31.3% | −79.6% |
| Diluted EPS | $-0.03 | $-0.04 | $-0.02 | $-0.10 | $-0.02 | $0.01 | $0.02 | $-0.03 | $-0.06 | $-0.02 | $-0.06 | $-0.17 |
| EBITDA | -$1.6M | -$4.2M | $575.0K | -$3.5M | -$1.0M | $3.7M | $4.8M | -$3.9M | -$5.8M | -$4.1M | -$10.2M | -$24.2M |
| Operating cash flow | -$2.2M | -$1.5M | -$9.2M | $1.3M | -$10.9M | -$8.9M | -$11.8M | $3.4M | -$4.6M | -$9.5M | $2.5M | -$9.2M |
| Free cash flow | -$2.4M | -$1.9M | -$9.2M | $1.3M | -$11.1M | -$9.0M | -$12.4M | $2.9M | -$5.2M | -$9.5M | $2.2M | -$10.0M |
| Diluted shares | 190.3M | 189.6M | 145.5M | 170.3M | 154.0M | 196.9M | 153.5M | 152.8M | 152.3M | 151.2M | 168.6M | 145.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $20.7M | $26.1M | $28.6M | $43.1M | $16.5M | $19.3M |
| Short-term investments | $21.9M | $18.7M | $18.0M | $12.4M | $24.1M | $31.4M |
| Total debt | $142.7M | $141.6M | $140.6M | $139.7M | $192.3M | $175.0M |
| Total assets | $252.3M | $246.2M | $255.9M | $248.9M | $232.1M | $235.8M |
| Total liabilities | $245.4M | $237.1M | $241.5M | $234.1M | $259.3M | $264.2M |
| Shareholders' equity | $6.9M | $9.1M | $14.3M | $14.9M | -$27.3M | -$28.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology